Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution... Show more
The Aroon Indicator for EDAP entered a downward trend on June 30, 2025. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 196 similar instances where the Aroon Indicator formed such a pattern. In of the 196 cases the stock moved lower. This puts the odds of a downward move at .
The Momentum Indicator moved below the 0 level on June 26, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on EDAP as a result. In of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for EDAP turned negative on June 30, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDAP declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 51 cases where EDAP's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EDAP advanced for three days, in of 248 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. EDAP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.581) is normal, around the industry mean (7.892). EDAP's P/E Ratio (100.000) is considerably higher than the industry average of (29.460). EDAP's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (4.521). EDAP has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.032). P/S Ratio (4.303) is also within normal values, averaging (35.215).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDAP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 81, placing this stock worse than average.
a developer of minimally invasive medical devices for urological diseases
Industry MedicalDistributors
A.I.dvisor tells us that EDAP and AORT have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EDAP and AORT's prices will move in lockstep.
Ticker / NAME | Correlation To EDAP | 1D Price Change % | ||
---|---|---|---|---|
EDAP | 100% | -5.99% | ||
AORT - EDAP | 29% Poorly correlated | +0.33% | ||
AVNS - EDAP | 21% Poorly correlated | -1.12% | ||
SRDX - EDAP | 21% Poorly correlated | -0.75% | ||
UFPT - EDAP | 20% Poorly correlated | -2.74% | ||
SENS - EDAP | 20% Poorly correlated | +3.03% | ||
More |